BriaCell Therapeutics (BCTX) Competitors $0.39 -0.01 (-2.82%) As of 01/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BCTX vs. TLSA, UNCY, GBIO, AVTE, BGM, FBLG, INCR, ANIX, IMRX, and CLSDShould you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Tiziana Life Sciences (TLSA), Unicycive Therapeutics (UNCY), Generation Bio (GBIO), Aerovate Therapeutics (AVTE), Qilian International Holding Group (BGM), FibroBiologics (FBLG), InterCure (INCR), Anixa Biosciences (ANIX), Immuneering (IMRX), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry. BriaCell Therapeutics vs. Tiziana Life Sciences Unicycive Therapeutics Generation Bio Aerovate Therapeutics Qilian International Holding Group FibroBiologics InterCure Anixa Biosciences Immuneering Clearside Biomedical BriaCell Therapeutics (NASDAQ:BCTX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability. Which has higher valuation & earnings, BCTX or TLSA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBriaCell TherapeuticsN/AN/A-$4.79M-$0.89-0.44Tiziana Life SciencesN/AN/A-$17.69MN/AN/A Does the media refer more to BCTX or TLSA? In the previous week, Tiziana Life Sciences had 5 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 2 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 1.59 beat Tiziana Life Sciences' score of 0.84 indicating that BriaCell Therapeutics is being referred to more favorably in the media. Company Overall Sentiment BriaCell Therapeutics Very Positive Tiziana Life Sciences Positive Do analysts prefer BCTX or TLSA? BriaCell Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 3,746.15%. Given BriaCell Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BriaCell Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BriaCell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BCTX or TLSA more profitable? Company Net Margins Return on Equity Return on Assets BriaCell TherapeuticsN/A N/A -44.65% Tiziana Life Sciences N/A N/A N/A Does the MarketBeat Community prefer BCTX or TLSA? Tiziana Life Sciences received 85 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote. CompanyUnderperformOutperformBriaCell TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesTiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Which has more volatility & risk, BCTX or TLSA? BriaCell Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Do institutionals & insiders have more ownership in BCTX or TLSA? 15.4% of BriaCell Therapeutics shares are owned by institutional investors. 5.7% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryBriaCell Therapeutics beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks. Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCTX vs. The Competition Export to ExcelMetricBriaCell TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.24M$6.54B$5.25B$8.80BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-0.3310.2185.9016.96Price / SalesN/A201.231,085.59118.01Price / CashN/A57.6743.2137.77Price / Book-2.604.885.044.89Net Income-$4.79M$154.38M$122.32M$228.40M7 Day Performance-9.70%-5.11%-2.79%-1.79%1 Month Performance-40.91%-3.16%-0.99%0.03%1 Year Performance-91.12%-4.64%23.59%13.56% BriaCell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCTXBriaCell Therapeutics3.0029 of 5 stars$0.39-2.8%$15.00+3,746.2%-91.1%$17.24MN/A-0.338Short Interest ↓Positive NewsTLSATiziana Life Sciences0.7727 of 5 stars$0.74+1.4%N/A+27.1%$78.03MN/A0.008Short Interest ↑UNCYUnicycive Therapeutics3.0678 of 5 stars$0.75-3.7%$5.13+583.2%-21.4%$77.86M$680,000.00-0.779Short Interest ↑GBIOGeneration Bio3.9929 of 5 stars$1.17+1.3%$7.50+543.8%-53.9%$77.81M$18.58M-0.53150Insider TradeNews CoverageGap UpAVTEAerovate Therapeutics0.9765 of 5 stars$2.69+0.4%$2.25-16.4%-87.8%$77.67MN/A-0.9051Short Interest ↑BGMQilian International Holding GroupN/A$10.56+12.7%N/AN/A$76.32M$29.87M0.00298Positive NewsHigh Trading VolumeFBLGFibroBiologics2.053 of 5 stars$2.20+3.8%$13.00+490.9%N/A$76.25MN/A0.0010Positive NewsGap UpINCRInterCure0.5639 of 5 stars$1.67+0.8%N/A+15.0%$76.11M$272.67M0.00350Short Interest ↑ANIXAnixa Biosciences2.6602 of 5 stars$2.36-0.8%$8.50+260.2%-51.5%$75.94M$210,000.00-6.055Earnings ReportUpcoming EarningsAnalyst ForecastNews CoveragePositive NewsIMRXImmuneering3.6723 of 5 stars$2.44+4.3%$12.80+424.6%-70.5%$75.76M$320,000.00-1.2460Analyst ForecastShort Interest ↓News CoverageGap UpCLSDClearside Biomedical3.256 of 5 stars$0.99+2.6%$5.33+436.1%-36.6%$75.45M$7.70M-2.2130Short Interest ↓Positive News Related Companies and Tools Related Companies TLSA Alternatives UNCY Alternatives GBIO Alternatives AVTE Alternatives BGM Alternatives FBLG Alternatives INCR Alternatives ANIX Alternatives IMRX Alternatives CLSD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCTX) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
